Iverjohn 12mg Tablet

Iverjohn 12mg contains ivermectin, but the approved use depends on the country and diagnosis.

• U.S.: FDA-approved oral ivermectin tablets are indicated for intestinal strongyloidiasis and onchocerciasis.

• Australia: TGA-approved oral ivermectin uses include onchocerciasis, intestinal strongyloidiasis and scabies, but Iverjohn-12 itself has been the subject of a TGA counterfeit-product warning.

• Scabies in the U.S.: Oral ivermectin is used off-label under clinical guidance; it is not FDA-approved for scabies.

• COVID-19: Ivermectin is not FDA-approved or authorized for prevention or treatment of COVID-19.

Condition	General reference regimen
Intestinal strongyloidiasis	Approximately 200 micrograms/kg as a single oral dose
Onchocerciasis	Approximately 150 micrograms/kg as a single oral dose
Classic scabies	200 micrograms/kg per dose, usually 2 doses 7–14 days apart; off-label in the U.S.

The U.S. prescribing information bases its weight-based tables on 3 mg tablets, so a 12 mg tablet should not automatically be treated as one standard adult dose. The appropriate dose depends on body weight, infection, age, medical history and the applicable treatment protocol. Do not calculate or repeat doses without medical advice.

• Take Iverjohn exactly according to the prescription or treatment instructions provided by your healthcare professional.

• For U.S.-labelled strongyloidiasis or onchocerciasis treatment, ivermectin tablets are taken on an empty stomach with water.

• For oral ivermectin used for scabies, CDC guidance recommends taking the dose with food to increase bioavailability.

• Do not substitute veterinary ivermectin for human ivermectin tablets.

• For strongyloidiasis, follow-up stool examinations may be needed to confirm that the infection has cleared.

Common or treatment-related effects may include:

• Dizziness or light-headedness

• Nausea, vomiting, diarrhea or abdominal discomfort

• Weakness or fatigue

• Headache or tremor

• Rash or itching

• Joint symptoms, fever or eye-related reactions during treatment of onchocerciasis

Ivermectin can interact with other medicines, including some blood-thinning treatments such as warfarin. Tell your doctor or pharmacist about all prescription medicines, non-prescription products and supplements before treatment. Seek urgent medical attention for seizures, severe confusion or drowsiness, breathing difficulty, blistering or peeling skin, or a severe allergic reaction.

Do not use Iverjohn if you have a known allergy to ivermectin or an ingredient in the tablet. Safety and effectiveness have not been established for children weighing less than 15 kg. Pregnancy and breastfeeding require medical assessment because treatment decisions depend on the infection, available alternatives and individual circumstances. People with significant exposure to Loa loa in West or Central Africa should tell their clinician before ivermectin treatment because serious neurological reactions can occur in heavily infected patients.

Australia-specific warning: the TGA has reported laboratory testing of imported Iverjohn-12 samples that found less ivermectin than the labelled 12 mg amount and classified the tested products as counterfeit. This was associated with specific imported samples and does not establish that every Iverjohn pack is counterfeit, but Australian customers should use reputable, authorized supply channels.

Do not take excessive doses or animal ivermectin products. Large human doses can cause serious toxicity, including neurological effects, seizures, low blood pressure and loss of consciousness. Ivermectin is not approved or authorized for COVID-19 treatment or prevention.

This information is for general education and does not replace advice from a doctor, pharmacist or qualified healthcare professional.